New Zealand markets close in 4 hours 59 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.2100+0.0400 (+1.84%)
At close: 04:00PM EDT
2.2100 0.00 (0.00%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.1700
Bid2.2000 x 29200
Ask2.2400 x 38500
Day's range2.1100 - 2.2900
52-week range1.6700 - 17.6500
Avg. volume9,250,825
Market cap476.613M
Beta (5Y monthly)4.69
PE ratio (TTM)N/A
EPS (TTM)-0.3470
Earnings date04 Aug 2022 - 08 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.38
  • Motley Fool

    2 Struggling Stocks That Aren't Likely to Recover Anytime Soon

    Two such stocks that could struggle for a long time to come are Ocugen (NASDAQ: OCGN) and Peloton Interactive (NASDAQ: PTON). Up until now, it has had nothing to show for its agreement with Bharat Biotech to help commercialize the Indian-based company's COVID-19 vaccine, Covaxin. Its agreements were to share in the profits of the vaccine in the Canadian and U.S. markets -- but Covaxin isn't approved for use in either country.

  • Zacks

    Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDA

    Ocugen (OCGN) gets respite after the FDA lifts the clinical hold on the company's phase II/III study, OCU-002, for Covaxin (BBV152).

  • GlobeNewswire

    Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

    NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines MALVERN, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that it is diversifying its innovative pipeline by introducing a Phase 3, cell therapy platform technology called NeoCart® (